Ofloxacin Sodium Chloride Injection

This product has a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative bacilli. It has good antibacterial activity in vitro against the following bacteria: most bacteria of the Enterobacteriaceae family, including Citrobacter, Enterobacter cloacae, Enterobacter aerogenes, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. It also has antibacterial activity against multi-drug resistant bacteria. It has high antibacterial activity against penicillin-resistant Neisseria gonorrhoeae, enzyme-producing Haemophilus influenzae and Moraxella. It has antibacterial activity against most strains of Pseudomonas such as Pseudomonas aeruginosa. This product has antibacterial activity against methicillin-sensitive Staphylococcus aureus, and only moderate antibacterial activity against Streptococcus pneumoniae, hemolytic Streptococcus and Enterococcus faecalis. It has good antimicrobial activity against Chlamydia trachomatis, Mycoplasma, Legionella, and also has antibacterial activity against Mycobacterium tuberculosis and atypical mycobacteria. Poor antibacterial activity against anaerobic bacteria. Ofloxacin is a bactericide that acts on the A subunit of bacterial DNA helicase, inhibiting DNA synthesis and replication, leading to bacterial death.

The main ingredient of this product is ofloxacin. Its chemical name is: (plusmn;)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-[1,4]benzoxazine-6-carboxylic acid.

This product is a light yellow-green clear liquid.

Applicable to infections caused by sensitive bacteria: 1. Urinary and reproductive system infections, including simple and complicated urinary tract infections, bacterial prostatitis, urethritis or cervicitis caused by Neisseria gonorrhoeae (including those caused by enzyme-producing strains). 2. Respiratory tract infections, including acute exacerbation of chronic bronchial infections and lung infections caused by sensitive Gram-negative bacilli. 3. Gastrointestinal infections caused by Shigella, Salmonella, enterotoxigenic Escherichia coli, Aeromonas hydrophila, Vibrio parahaemolyticus, etc. 4. Typhoid fever. 5. Bone and joint infections. 6. Skin and soft tissue infections. 7. Sepsis

Intravenous drip. Common dosage for adults: 1 Bronchial infection, lung infection: 0.3g (calculated as ofloxacin, the same below), twice a day, the course of treatment is 7 to 14 days. 2 Acute simple lower urinary tract infection: 0.2g once, twice a day, the course of treatment is 5 to 7 days; complicated urinary tract infection: 0.2g once, twice a day, the course of treatment is 10 to 14 days. 3 Prostatitis: 0.3g once, twice a day, the course of treatment is 6 weeks; Chlamydia cervicitis or urethritis, 0.3g once, twice a day, the course of treatment is 7 to 14 days. 4 Simple gonorrhea: 0.4g once, single dose. 5 Typhoid fever: 0.3g once, twice a day, the course of treatment is 10 to 14 days. The dose can be increased to 0.4g once, twice a day for Pseudomonas aeruginosa infection or more severe infection.

1 Gastrointestinal reactions are relatively common and may manifest as abdominal discomfort or pain, diarrhea, nausea or vomiting. 2 Central nervous system reactions may include dizziness, headache, drowsiness or insomnia. 3 Allergic reactions: rash, skin itching, and occasionally exudative erythema multiforme and angioedema. A small number of patients have photosensitivity reactions. 4 Occasionally, the following may occur: (1) Epileptic seizures, mental abnormalities, irritability, confusion, hallucinations, and tremors. (2) Manifestations of interstitial nephritis such as hematuria, fever, and rash. (3) Phlebitis. (4) Crystalluria, which is more common when used in high doses. (5) Joint pain. 5 A small number of patients may experience elevated serum aminotransferases, elevated blood urea nitrogen, and decreased peripheral white blood cells, which are mostly mild and transient.

Patients who are allergic to this product and quinolones are contraindicated.

1 Urine alkalinizing agents can reduce the solubility of this product in urine, leading to crystalluria and nephrotoxicity. 2 When this product is used in combination with theophylline, competitive inhibition of the binding site of cytochrome P450 may lead to a significant reduction in the elimination of theophylline in the liver, a prolonged elimination half-life (t1/2), an increase in blood concentration, and the appearance of symptoms of theophylline poisoning, such as nausea, vomiting, tremor, restlessness, excitement, convulsions, palpitations, etc., so it should be avoided to use it in combination. If it cannot be avoided, the blood concentration of theophylline should be measured and the dose should be adjusted. 3 When cyclosporine is used in combination with this product, its blood concentration increases. The blood concentration of cyclosporine must be monitored and the dose adjusted. 4 When this product is used in combination with the anticoagulant warfarin, it can enhance the anticoagulant effect of the latter, so the combination of the two should be avoided. If it cannot be avoided, the patient's prothrombin time should be closely monitored and the dose adjusted. 5 Probenecid can reduce the secretion of this product from the renal tubules by about 50%. When used in combination, it may cause toxicity due to the increased blood concentration of this product. 6. This product interferes with the metabolism of caffeine, which leads to a decrease in caffeine elimination, a prolongation of the blood elimination half-life (t1/2), and may produce central nervous system toxicity, so the two should be avoided together. If it cannot be avoided, the patient's blood caffeine concentration should be closely monitored and the dosage adjusted.

Seal and store.

100ml: Ofloxacin 0.2g and sodium chloride 0.9g

Sichuan Meidakang Huakang Pharmaceutical Co., Ltd.

• Founded in:

  2001-02-27

• Address:

  No. 1 Zhenjiang Road, Jiangsu Industrial Park, Mianzhu Economic Development Zone, Sichuan

• Tax NO.:

  915106836208704965

• Registered Funds:

  160 million yuan

• Website:

  Log in to view

• Email:

  Log in to view